Vagus Nerve Stimulation Therapy for Treatment of Drug-Resistant Epilepsy and Depression

Shoaib Shafique, Michael C. Dalsing

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Vagal nerve stimulation therapy is a new adjunctive treatment for drug-resistant epilepsy and depression. It consists of a pulse generator that transmits impulses to the left vagus nerve via an implantable electrode and can be performed by surgeons familiar with the anatomy of the cervical vagus nerve. The minimum age for vagal nerve stimulation therapy for epilepsy is 12 years, and for depression, 18 years. Hoarseness and cough are the most common side effects. Response rates to vagal nerve stimulation therapy vary and depend on several other factors. If used as adjunctive therapy, vagal nerve stimulation has shown better control of seizures or depression at smaller doses of antiepileptic or antidepressive medications and also results in decreased dose-dependent side effects. Vagal nerve stimulation therapy appears safe as an adjunctive treatment for drug-resistant epilepsy and depression. Long-term data are needed to better define its ultimate role in various subsets of patients.

Original languageEnglish (US)
Pages (from-to)323-327
Number of pages5
JournalPerspectives in vascular surgery and endovascular therapy
Volume18
Issue number4
DOIs
StatePublished - Dec 2006

Fingerprint

Vagus Nerve Stimulation
Vagus Nerve
Therapeutics
Hoarseness
Implanted Electrodes
Drug Resistant Epilepsy
Cough
Anticonvulsants
Epilepsy
Anatomy
Seizures

Keywords

  • drug-resistant epilepsy
  • treatment-resistant depression
  • vagus nerve stimulation therapy

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Vagus Nerve Stimulation Therapy for Treatment of Drug-Resistant Epilepsy and Depression. / Shafique, Shoaib; Dalsing, Michael C.

In: Perspectives in vascular surgery and endovascular therapy, Vol. 18, No. 4, 12.2006, p. 323-327.

Research output: Contribution to journalArticle

@article{ffaffad766ce4af2ad4b5028fad56b90,
title = "Vagus Nerve Stimulation Therapy for Treatment of Drug-Resistant Epilepsy and Depression",
abstract = "Vagal nerve stimulation therapy is a new adjunctive treatment for drug-resistant epilepsy and depression. It consists of a pulse generator that transmits impulses to the left vagus nerve via an implantable electrode and can be performed by surgeons familiar with the anatomy of the cervical vagus nerve. The minimum age for vagal nerve stimulation therapy for epilepsy is 12 years, and for depression, 18 years. Hoarseness and cough are the most common side effects. Response rates to vagal nerve stimulation therapy vary and depend on several other factors. If used as adjunctive therapy, vagal nerve stimulation has shown better control of seizures or depression at smaller doses of antiepileptic or antidepressive medications and also results in decreased dose-dependent side effects. Vagal nerve stimulation therapy appears safe as an adjunctive treatment for drug-resistant epilepsy and depression. Long-term data are needed to better define its ultimate role in various subsets of patients.",
keywords = "drug-resistant epilepsy, treatment-resistant depression, vagus nerve stimulation therapy",
author = "Shoaib Shafique and Dalsing, {Michael C.}",
year = "2006",
month = "12",
doi = "10.1177/1531003506297200",
language = "English (US)",
volume = "18",
pages = "323--327",
journal = "Perspectives in Vascular Surgery and Endovascular Therapy",
issn = "1531-0035",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Vagus Nerve Stimulation Therapy for Treatment of Drug-Resistant Epilepsy and Depression

AU - Shafique, Shoaib

AU - Dalsing, Michael C.

PY - 2006/12

Y1 - 2006/12

N2 - Vagal nerve stimulation therapy is a new adjunctive treatment for drug-resistant epilepsy and depression. It consists of a pulse generator that transmits impulses to the left vagus nerve via an implantable electrode and can be performed by surgeons familiar with the anatomy of the cervical vagus nerve. The minimum age for vagal nerve stimulation therapy for epilepsy is 12 years, and for depression, 18 years. Hoarseness and cough are the most common side effects. Response rates to vagal nerve stimulation therapy vary and depend on several other factors. If used as adjunctive therapy, vagal nerve stimulation has shown better control of seizures or depression at smaller doses of antiepileptic or antidepressive medications and also results in decreased dose-dependent side effects. Vagal nerve stimulation therapy appears safe as an adjunctive treatment for drug-resistant epilepsy and depression. Long-term data are needed to better define its ultimate role in various subsets of patients.

AB - Vagal nerve stimulation therapy is a new adjunctive treatment for drug-resistant epilepsy and depression. It consists of a pulse generator that transmits impulses to the left vagus nerve via an implantable electrode and can be performed by surgeons familiar with the anatomy of the cervical vagus nerve. The minimum age for vagal nerve stimulation therapy for epilepsy is 12 years, and for depression, 18 years. Hoarseness and cough are the most common side effects. Response rates to vagal nerve stimulation therapy vary and depend on several other factors. If used as adjunctive therapy, vagal nerve stimulation has shown better control of seizures or depression at smaller doses of antiepileptic or antidepressive medications and also results in decreased dose-dependent side effects. Vagal nerve stimulation therapy appears safe as an adjunctive treatment for drug-resistant epilepsy and depression. Long-term data are needed to better define its ultimate role in various subsets of patients.

KW - drug-resistant epilepsy

KW - treatment-resistant depression

KW - vagus nerve stimulation therapy

UR - http://www.scopus.com/inward/record.url?scp=34347232348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347232348&partnerID=8YFLogxK

U2 - 10.1177/1531003506297200

DO - 10.1177/1531003506297200

M3 - Article

C2 - 17351201

AN - SCOPUS:34347232348

VL - 18

SP - 323

EP - 327

JO - Perspectives in Vascular Surgery and Endovascular Therapy

JF - Perspectives in Vascular Surgery and Endovascular Therapy

SN - 1531-0035

IS - 4

ER -